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Harmonisation of Biobank Regulations in Africa: Lessons to be learned from Europe 
1. Introduction 
Since the success of the human genome project, biobanks have become integral in understanding 
the complex interplay between genetics and the environment in the development of diseases.1  The 
development of genomic biobank research has demonstrated that research is increasingly no longer 
confined to one site, but is now often a global, multi-site affair. Biological samples can not only be 
used and reused, but clinical information can continue to be added to the sample.2 These samples 
are easily transferred across borders and more and more research is reliant on access to these 
biological samples.3 
Yet the governance of this research is challenging. At a local level the biobank is likely to have its 
own rules and procedures in place. These must be followed as well as any guidelines issued by the 
research ethics committee (REC). Nationally, legislation, regulations and national ethical guidelines 
may have specific provisions on biobank research. Internationally, treaties, directives or agreements 
may have relevance, as well as the guidelines from professional bodies such as the International 
Society for Biological and Environmental Repositories (ISBER). However, due to the globalisation of 
the research, many biobanks are collaborating together as part of international consortia and 
sharing samples. These international consortia, as well as their funders, will also have their own 
individual rules in place. This poses particular problems for researchers attempting to access these 
samples as they must now navigate the governance frameworks in each jurisdiction that the 
individual biobanks reside. Added to this complexity is that these laws, guidelines, frameworks and 
policies are often in conflict, leading to confusion for researchers and challenging the development 
and efficacy of collaborations. Unsurprisingly, this has led to calls for harmonisation at a 
transnational level.4 
Despite these challenges, there has been an emergence of large and small scale biobanks across the 
world and an increasing number of biobank networks. International consortia such as the Public 
Population Project in Genomics and Society (P³G) and the International Society for Biological and 
Environmental Repositories (ISBER) seek to promote collaborations and set standards, whilst 
protecting national laws and policies. Yet these developments have largely been focused in the 
developed world and until recently the African continent was largely neglected. Recently there has 
been a growth in local and national biobanks in Africa and this has been spurred on by the Human 
Hereditary and Health in Africa (H3Africa) project.  
Although these developments are welcomed, the governance of biobanks raise particular problems 
in Africa. There is considerable cultural diversity across the continent and biological samples often 
have special significance not seen in the West. The H3Africa project requires collaboration across 
borders, but the extent to which governance frameworks can be harmonised may be challenging. 
However, lessons may be learned from the European experience as Africa scales up its biobank 
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research efforts and this will be the subject of this paper. It will first consider the challenges in 
biobank governance generally before discussing biobank research in Africa. It will also examine the 
emergence of biobank governance in Europe and lessons that may be learned for Africa. While a 
clear governance framework in Africa can enhance the research process by facilitating collaborations 
between researchers in Africa and around the world, this paper will question whether a unified 
harmonised framework is possible or even desirable for Africa. 
2. Governing biobanks: the challenges  
Biobanks are a valuable resource in medical research as they can store large quantities of biological 
materials that can be readily accessed by researchers across the world. To date, the governance of 
biobank research has tended to fall within the traditional governance structures of medical research. 
This involves a mix of national legislation and regulations as well as REC requirements. However this 
system is not particularly suitable for biobank research as it is a system that is designed for one 
research project in one institution and jurisdiction and approval is required by the REC in the 
institution that it takes place. 5  Approval is front loaded, taking place prior to the commencement of 
the research, and the focus is on getting the protocol through the REC and the informed consent 
process. 6 
With biobank research, the storage of the biological sample is potentially indefinite and it can be 
reused in multiple research projects. This potential to reuse the sample gives it considerable value 
but it questions our traditional informed consent process. It can be difficult to re-contact donors 
each time the sample is to be used, thus there have been calls for broad consent, backed by the 
WHO and OECD, whereby donors can consent to future but unspecified uses of the sample.7 
Although such an approach is consent, it is certainly not informed, thus tiered consent8 and dynamic 
consent9 have all been advocated as alternatives in an attempt to strike a balance between 
protecting human participants and allowing the research to flourish. If we are to adopt these new 
forms of consent, the focus must be taken away from the informed consent process as being at the 
start of the research only, in favour of some form of ongoing consent. Who oversees this process is 
unknown, but it demonstrates the need to look at other forms of governance and oversight for this 
research.  
These are all issues that individual jurisdictions must address, but are further complicated by the 
transnationalisation of the research, particularly where the research is being done by international 
consortia. Biological samples can easily be moved across borders and open access policies are a 
condition of many funders.10 The governance frameworks remain nationally based and not in favour 
of open science, but are being used to govern this transnational research that relies on open science 
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policies. This can be time consuming and costly as researchers spend time trying to ascertain the 
rules in each jurisdiction, and rules and policies are often in conflict. In response many organisations 
are developing their own guidelines to govern the research.  
Rather than clarify matters, we are left with a multitude of laws, policies, guidelines, standard 
operating procedures, frameworks and agreements. There is no consensus on the legal and ethical 
framework for governance and the state has less of a role. 11 National rules and policies will continue 
to have an important function, but bottom-up approaches to governance from local biobanks and 
also from public opinion is of increasing importance.12  
Biobank research is not alone in the search for new governance frameworks as it is an issue for many 
new and emerging technologies. There are increasing calls for “better” or “smarter” regulation as 
interest groups, institutions and individual actors involved in governance grows.13 The state is having 
less of a role to play as the influence of international bodies and in particular funding agencies grow. 
We are seeing a rise of new forms of governance that are informal, flexible, decentralised and 
polycentric.14 
It is certain that what we do need is a flexible governance structure that can meet the demands of 
biobank research. The research is developing at such a pace that over prescriptive provisions may 
quickly become out-dated. However, how should this be balanced with the need to have detail to 
ensure that the rules to be followed are clear, consistent, legitimate and transparent in Africa? 
Principles based regulation (PBR), that moves away from prescriptive rules to high level principles, 
has been mooted for innovative technology.15 Amid concerns that Europe seeks to “regulate 
everything”, van Veen has proposed such a model that is based on a good governance framework 
and key principles such as transparency, accountability, the non-profit basis of biobanks, intellectual 
property rights and confidentiality of personal data, amongst others.16 Such a model may be suitable 
for biobank research as the key issues tend to focus on consent, feedback to participants, public 
interest, protection of process, access, ownership and intellectual property rights.17 The Tiss.eu 
project has reported that the differences in procuring, storing and transferring human tissues 
diverge at a national and institutional level making harmonisation “extraordinarily difficult.” 
However there are commonalities between these policies that “might pave the way for an 
intensified exchange and adoption of existing national approaches and models.”18 Common goals 
and principles are applied to a particular research project and it avoids the problem of laws 
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becoming outdated. Other research consortia have established particular governance structures 
known as ‘Pop-up’ governance to address issues particular to that consortium.19 
However both PBR and pop-up governance cannot exist in a vacuum. Pop-up governance can only 
exist when there is an external governance framework in place.20 Equally Devaney acknowledges 
that the flexibility of PBR must be tempered with some descriptive rules to assist with interpretation 
and compliance.21 What is probably necessary is a combination of both. Due to the multitude of 
actors involved in governance, that includes but is not led by the state, governance is polycentric.22 It 
requires sufficient flexibility that researchers can do their work without fear of the rules becoming 
outdated and that rules can be adapted to local circumstances. Yet it also requires sufficient detail 
so that more guidelines and policies are not required to develop to fill the vacuum left in the 
governance system.23 
How can all of this be achieved so that there is some level of harmonisation of governance in Africa 
to encourage and support collaboration, while also ensuring that there is not an over proliferation of 
rules and procedures to fill perceived governance gaps? Embedded in this is the challenge of cultural 
diversity. Before Africa rushes towards a harmonisation of its governance framework, we must first 
consider whether it is desirable or achievable. 
2.1 Biobanking in Africa 
Globally, biomedical research is disproportionately favoured towards those populations who can 
afford medical research. An estimated 10% of research funds is focused on diseases that affect 90% 
of the world’s population to the benefit of those in developed countries.24 Genomic research is no 
different with genomic wide association studies generally focusing on populations of European 
descent,25 thus perpetuating this global health inequality.26 Africa is the most genetically diverse 
continent and the Khoe-San people from southern Africa have the world’s oldest genetic lineage.27 
Yet previously the only involvement of the African population in genomic research was in the form 
of “parachute research” whereby samples were collected from African populations and used in labs 
in other developed countries, often without the knowledge of the donor and also without the 
involvement of any local investigator or researcher.28 In parachute research, the samples are used in 
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labs in other developed countries, often without the knowledge of the donor and also without the 
involvement of any local investigator or researcher.29 As the sample is removed from its country of 
origin, not only has the research very little local impact, but this prevents the development of local 
capacity, infrastructure and expertise.30 Tellingly, in a survey of 50 publications on PubMed that used 
Cameroonian DNA samples, only 14 publications had a local author.31  
Unsurprisingly, this has led to a widening gap in clinical and laboratory research capacity between 
sub-Saharan Africa and other developed nations.32 Inequalities in health research can often lead to 
inequalities in health33 and parachute research does little to resolve this. Rather it leaves the African 
population with little control over the fate of these samples and their future use, and there is little 
incentive for sample recipients to use these samples in a manner that safeguards the interests of 
donors. Donors have clear preferences on the use, reuse and exportation of their sample,34 but if 
these are removed from the country of origin, their preferences may not be enforceable. There is 
thus a real need to refocus the debate to respecting the rights of the African population, from first 
obtaining the sample, to the building up of the research programme, through to the establishment 
of a clear regulatory framework that protects donor and researcher interests.  
The International HapMap project35 and the Malaria Genomic Epidemiology Network (MalariaGEN)36 
began to develop genomic biobank capacity in Africa. However the H3Africa project is the biggest 
attempt at establishing biobanks in Africa. As well as improving research in Africa,37 the H3Africa 
project seeks to improve intra-Africa collaborations, build up the necessary infrastructure and 
capacity and establish African biobanks. It aims to keep the samples in Africa for use by African 
researchers, thus addressing some of the exportation and exploitation concerns.38 The project is a 
great opportunity for the continent in terms of resources and capacity development, as well as 
research that is targeted at the population, but also presents considerable legal and ethical 
challenges in the governance of this research. Consent, confidentiality and commercialisation are all 
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to be addressed, but added to this is the importance of the community in African society as well as 
the cultural significance of blood and other biological samples in many communities.39 
Part of the H3Africa project is a mandate to address the ethical, legal and social issues that arise in 
the research and the Working Group on Social and Ethical Issues are seeking to introduce policies on 
many of the issues raised.40 However, although the H3Africa project is bringing many of these issues 
to the fore, other biobanks independent of the H3Africa project are being set up across the 
continent.41 These biobanks all have differing local, national and international rules and policies to 
follow. For example, in South Africa, oversight of research is done by the REC in each institution. Due 
to the particular issues involved and the scientific expertise necessary, the University of 
Witwatersrand has established its own Biobank Ethics Committee and separate policies on the 
establishment of a biobank.42  At a national level, there is the National Health Act 2003 and 
accompanying regulations promulgated in 2012 that govern the use of tissues as well as the 
exportation of tissues. The Department of Health’s ethical guidelines must also be followed.43 The 
South African governance system permits broad and tiered consent as well as exportation of 
samples, subject to certain conditions. This is in contrast to other African countries that do not have 
specific pronouncements on consent or exportation, yet South African institutions may wish to 
collaborate with institutions from these other countries. 
Governance frameworks differ across countries on the continent and it is in this environment that 
H3Africa is seeking to encourage and promote collaboration. Arguably for this to occur there will be 
a need for some harmonisation across jurisdictions. H3Africa can be a vehicle for harmonisation, but 
there is the danger that it will only add to the growing number of policies in this area. An 
overpopulation of conflicting biobank policies and regulations will do little to promote collaboration 
but will rather be a real challenge to governing biobank research in Africa. Good governance ensures 
clarity on the policies to be followed for the researcher; like issues should be similarly treated, 
thereby encouraging consistency and promoting the integrity of the biobanks.44 Thus before the 
H3Africa project seeks to start a harmonisation drive, considerable of what is possible and 
achievable is necessary. 
2.3 Biobank governance in Europe 
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Biobanks in Europe are governed by international guidelines, Council of Europe recommendations, 
European Union (EU) regulations, national regulations, legislation and guidelines, REC guidelines, 
funding body requirements, guidelines established by the biobank itself and any consortia to which 
it belongs. This mix of local, national and transnational regulation can be problematic as they each 
have differing legal status and often overlap and contradict. The use, re-use and transfer of samples 
require a navigation of these regulations as well as the consent under which the sample was 
obtained. It can lead to difficulty in international collaborative research which relies on the transfer 
of biological samples across borders as well as confusion for those seeking access to the sample. It is 
thus unsurprising that the European Commission has claimed that harmonisation of biobank 
frameworks is necessary to ensure the cross border transfer of samples and research, as currently 
national policies are often in conflict negatively impact cross border initiatives and collaboration.45 
First to consider are the international guidelines from the World Medical Association,46 the World 
Health Organisation (WHO)47, the OECD48 and the UNESCO Declaration on the Human Genome and 
Human Rights.49 They cover topics such as consent and confidentiality, but are non-binding and 
Europe is under no obligation to follow them. At a European level, the Council of Europe issued a 
recommendation on the exchange and transfer of biological samples in 197950 and human tissue 
banks in 1994.51 Its most recent recommendation focused on research on human biological origins 
acknowledges that research is increasingly international and involving large quantities of biological 
samples.52 The recommendation seeks to protect the rights of participants in biobank research and 
discusses consent, storage and anonymisation, amongst other issues.53 As the first official European 
document on research on biological samples54 it is significant, but there are some notable omissions 
from this recommendation including the ownership of samples, incidental findings as well as the use 
of biological samples from minors.55 Furthermore it is a recommendation only, intended to provide 
guidance to Member States in drafting legislation rather than have any legal force itself.  
Despite the non-enforceability of these international conventions, they do have a function. They can 
start a debate on biobank research and also provide a framework for individual biobanks and 
jurisdictions where none may exist. They also are part of PBR advocated by Devaney.56 In the African 
context this is particular useful as it allows for cultural diversity. However they are quite general in 
nature, setting out principles rather than standards or procedures on the storage and use of samples 
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and data.57 They are also subject to interpretation, and differences in interpretation could 
potentially impede collaborations. Furthermore as illustrated, they are often non-binding leaving 
individual jurisdictions free to decide which, if any, sections to implement, and this is not a suitable 
approach for achieving a harmonised framework.  
Unlike the OCED, the WHO and the Council of Europe, the treaties, directives and regulations of the 
EU have the force of law and must be followed by the Member States. Importantly, for some time 
the EU has been concerned with the promotion of good governance frameworks and in an effort to 
reduce bureaucracy and improve the regulatory process, it has sought to improve its legal proposals, 
reducing unnecessary or over-lapping rules and making its laws more understandable.58 Known as 
‘Better Regulation’ it is based on seven common principles: necessity, proportionality, subsidiarity, 
transparency, accountability, accessibility and simplicity.59 Since 2010, the European Commission has 
also focused on smart regulation which is about “the whole policy cycle - from the design of a piece 
of legislation, to implementation, enforcement, evaluation and revision.”60 Part of this will be on 
ensuring that regulations are only introduced where necessary and in a manner that will improve the 
governance framework. Applying this to biobank research, new regulations should only be 
introduced if deemed necessary, based on an examination of the current policy and frameworks in 
place and the governance framework should follow the seven principles of Better Regulation. 
A second important factor in this European governance is that the competences of the EU are to 
create an internal market and monetary union.61 Research does not fall under these competences, 
but the European Commission has begun to take a much more active role in health since the 
Maastricht Treaty. This increased activity has not brought with it a coordinated response to 
regulating research and has very little impact on biobanking research. The Clinical Trials Directive has 
some influence as it requires an REC to review research and informed consent is necessary prior to 
the donation of a sample, but beyond this it has little impact. The safety and quality of tissues have 
also been addressed, but this applies to therapeutic use only and not research resulting in a lack of 
specific regulations for biobanks.62 Thus despite the potential of the EU to introduce some 
harmonisation, none has been forthcoming.  
One exception is in relation to data. Data, including data from an identifiable biological sample, is 
governed by the Data Protection Directive.63 This directive was introduced in a response to the 
recognition that differing national legislation was potentially preventing the transfer of data across 
Member States, but it also seeks to protect the privacy of individuals. However protections in the 
directive pertain to data only and not the biological sample.64 There thus seems to be a distinction in 
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law between data and the biological samples from which data is extracted65 and different consent 
requirements can apply to the sample and data. It does seem rather peculiar that there was a need 
to regulate the data but not the sample itself, but for now, the protection of biological samples is not 
part of the European constitutional order. However, what the Data Protection Directive does 
demonstrate is that full harmonisation is not always possible, as its implementation differs across 
Member States. The directive requires that stored data be anonymised, but many jurisdictions 
consider that double coding is acceptable.66 This can lead to challenges as if there is no one model 
for sharing data, comparisons between studies may be problematic.67  
A final point to note is that the EU has no role in the regulation of ethics. The European Group on 
Ethics (EGE) was established to provide ethical guidance to the European Commission68 and in 1998 
it released an Opinion on human tissue banking that recommended European standards on safety 
and quality.69 However, although regulations were subsequently introduced on this matter, it is an 
advisory body only and there is no obligation for the Commission or the Member States to follow its 
Opinions. Thus its Opinions has the same fate as many international guidelines: they may start 
debate and provide guidance, but unless adopted by the Commission, have no enforceability. 
2.3.1 Biobank governance in Europe-has harmonisation hindered development? 
It is therefore the responsibility of the Member States to govern biobank research and they differ in 
their approach: some have developed specific legislation, while others have provisions integrated 
into wider legislative provisions.70 There are some common trends between countries: generally 
accreditation should be sought by a relevant competent authority, a registry of biobanks should be 
established with the coding of samples if they cannot be anonymised.71 Certain national bodies such 
as the Human Tissues Authority in the UK have some national oversight. However that is generally 
limited to the issuing of licences for research and ensuring compliance with the law. Oversight of the 
use of sample is primarily conducted at a local REC level that are tasked with reviewing biobank 
protocols. Thus governance of biobanks can vary according to the individual jurisdiction and the 
individual biobank.  
The lack of a harmonised governance framework in Europe has meant that the secondary use of 
samples in one country may be prohibited or restricted in another and may result in the unlawful 
use of samples where collaborations require the sharing of samples across borders.72 There has been 
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considerable uncertainty in how best to address these challenges,73 with many calling for a pan-
European infrastructure for the ethical, legal and social issues (ELSI).74 In recent years, EU funded 
projects have begun to consider these issues through a project on the implementation of the Data 
Protection Directive in medical research (PRIVIREAL), protection of fundamental rights and privacy in 
relation to genetic information and biobanks (PRIVILEGED), confidentiality and protection of data 
(Tiss.EU), amongst others.75 Many organisations and institutions have also sought to develop best 
practices on the technical aspects of biobanks as well as for the ethical and legal issues, in the hope 
that this can promote a unified approach to biobank research.76 However, these organisations must 
still operate within the differing legal frameworks of each state, a real challenge in the development 
of large scale collaborative projects, and can lead to duplication of effort and wastage of resources.77  
Yet the recognition that harmonisation efforts could encourage the fluid interchange of samples and 
data across borders,78 has seen efforts to reach this goal continue. Of significance is Article 179 and 
187 of the TFEU on the establishment of a European Research Area and structures that may be 
necessary to develop research within the Union. Out of this, the European Research Infrastructure 
Consortium (ERIC) was established to provide the legal framework for the establishment of research 
infrastructures across Europe.79 In 2006, the European Strategy Forum on Research Infrastructures 
(ESFI) recommended the establishment of the biobanking and biomolecular resources research 
infrastructure (BBMRI)80 to  
“integrate the existing quality controlled biobanks, biomolecular resources and enabling 
technologies into a novel pan-European biomedical Research Infrastructure, and guided the 
way towards the establishment of high quality de novo European biobanks”.81  
The preparatory phase (PP) of the project lasted between 2008 and 2011 and €5 million was granted 
to fund the conceptualisation and securing of funding for the BBMRI.82  It sought to collect biological 
samples that are linked to continually updated health information and to be a coordinating hub of 
activities, including collection, management, distribution and analysis of samples from European 
Member States.83 This phase also involved a review and analysis of the ethical, legal and social issues 
that resulted in the coordination of the ethics review process, a policy on the protection of cross-
border data and the development of tools to promote harmonisation. These included a WIKIE+ legal 
platform to disseminate documents currently used in EU countries and other web based tools on the 
legal requirements for the transfer of samples and transparency in transfer.84 In November 2013, the 
BBMRI became an ERIC (BBMRI-ERIC) with its seat in Austria. Rather than devising a new set of 
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regulations or guidelines for its members, it was decided that the laws of the country in which the 
research is conducted will govern it.85  
BBRMI-ERIC has thus sought to find a solution that is workable in light of the current European 
governance framework. Its solution does not eradicate the challenges of the applicability of different 
laws and policies, but it is a platform that can help researchers navigate the myriad of laws, 
regulations and policies. Furthermore it may possibly influence EU policy by promoting the interests 
of the ERIC86 and be a key player in a drive for a harmonised framework in Europe. 
3. Governing biobanks in Africa: lessons to be learned 
One of the greatest challenges to a harmonised biobank governance framework, both in Africa and 
around the world, is that the research is being conducted at a supranational level, but governance is 
still at a national level.87 To resolve this problem in Europe, Kaye has recommended the 
development of a uniform regulatory structure and the establishment of a new independent 
European entity or body currently in existence that has enforcement powers and the ability to 
develop standards for biobanks.88 The advantage of such a body is that the principles and standards 
would apply irrespective of the establishment of any new biobank.89 This system remains elusive for 
Europe, but has not stopped the research from developing. Moving forward, Africa may consider 
that harmonisation has not been achieved in Europe, but note that there are a number of key points 
that should be considered as biobank research develops on the continent. 
3.1 Importance of good governance 
Biobank research in Africa is governed by a combination of local and national laws, regulations and 
guidelines. Similar to Europe, in some jurisdictions biobank research falls under general provisions 
on the use of tissue, while in others there are genomic biobank research specific policies. Coupled 
with this, there is the Declaration of Helsinki and other international agreements that must be 
considered and more recently, the H3Africa policies on informed consent, community engagement 
as well as the other policies that the group is currently developing. 
A harmonisation of policies could assist in the development of collaborations to be formed under the 
H3Africa project. Incorporating differing national consenting requirements into one collaborative 
project, can lead to complicated consent forms for multi-national projects. A study by McGibbons et 
al revealed that potential collaborators from jurisdictions that had overly strict consenting 
requirements were excluded.90 Unclear or inconsistent policies has forced some into taking more 
governance related steps than were probably necessary to make sure that they were compliant,91 
while others creatively interpreted the rules or selected those to be followed.92 This proliferation of 
differing rules and procedures in Europe were in part due to the uncertainty in biobank governance 
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in Europe, where at times researchers were forced to rely on their past professional experience as a 
basis in which to develop governance frameworks for the research.93  
An over population of contradictory regulations and policies has meant that researchers often have 
to decide which to follow in Europe. The current system in Europe and the emerging trend in Africa 
is that biobanks are governed through a combination of national regulations and guidelines, with 
oversight generally in the hands of a local REC, leading to a confusing and bewildering governance 
space. Having multiple and sometimes contradictory ethics review can undermine transparency and 
accountability in any governance system.94 This system should not be made any more confusing by 
creating a new set of rules or principles. Rather, attention should be given to the features of a good 
governance framework for Africa. Crucially the system must be flexible and adaptable to meet the 
developing science. Overly prescriptive legislation can quickly become outdated and may not be 
suitable for innovative research on the continent. The UK Biobank has developed an Ethics and 
Governance Framework (EGF) that is continuously revised and it’s Ethics and Governance Council 
(EGC) develops policies and procedures as well as monitoring and overseeing the UK Biobank. Both 
the EGF and the EGC are continuously revised and updated and the EGC continuously has an open 
dialogue with the UK Biobank.95 Laurie has argued that this type of “reflexive governance” whereby 
policies change over time in response to stakeholder deliberations and changing needs is much more 
suited to governing biobanks than hard law as it remains fit for purpose.96 This continuing 
involvement of stakeholders is particularly important for African populations due to the importance 
of the community in African society.97 There is a need for ongoing consultation with the community 
and its leaders throughout the project to seek their views on issues such as consent, 
commercialisation of research and feedback of results. The importance of community engagement 
for biobank research, particularly in Africa, must be recognised and a reflective governance 
framework that provides for this is to be welcomed. 
With this in mind, a PBR approach that has certain key principles underpinning its governance 
framework may be most suitable. Laurie considers that the role of the law may thus be best 
confined to the protection of core principles or interests that should underpin biobank research.98 
The H3Africa High Level Principles on ethics governance and resource sharing are key values that 
underpin the Consortium, with discretion on how these principles are implemented. 99 Such an 
approach does bring with it flexibility, but is problematic for two reasons. First, regulations on 
biobank research across the continent are developed in isolation, with little or no regard for how 
their regulations will impact other jurisdictions. These principles are potentially subject to 
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considerable differences in interpretation and this will do little to improve harmonisation across the 
continent. Second, only those projects funded by H3Africa are subject to the principles and they are 
not enforceable across the entire continent. A pan-African response to biobank research would be 
preferable as it would speak for the continent rather than those in receipt of H3Africa funds. 
H3Africa does not have the authority to speak for the entire continent, and we may see the 
emergence of other guidelines and policies spring up for biobank research in Africa that may claim to 
speak for particular groups across the continent.   
However due to its position, H3Africa can play a leading role in this, in much the same way as BBMRI 
is playing in Europe. The ethos of smart regulation whereby only necessary regulations are to be 
introduced should be endorsed by the Consortium. Its focus should equally be on the promotion of 
good governance as well as the substance of the policies in place. In their study on the governance 
on the use of biological data and samples in England and Wales, McGibbons et al found that the 
system did not follow the principles of good governance. It lacked consistency due to the lack of 
coordination and single body for decisions making, the system lacked transparency as it reportedly 
difficult to know what rules applied and who was to enforce the rule and due to the considerable 
financial and resource costs involved, the system was not proportionate.100  
Currently, biobank research in Africa can be subject to similar criticisms. There is no one body 
responsible for coordination of activities either nationally or for the continent, and it is often difficult 
to know what rules to follow. For example, if funding conditions require open access policies that 
may be contrary to the rules in one jurisdiction, what are the implications for the researcher and can 
they be removed from the Consortium? H3Africa should take a lead in outlining the features of a 
good governance framework for biobank research in Africa. The “Better Regulation” Principles 
adopted by the European may be a good starting point, but these should be adopted for biobank 
research on the African continent.  
3.2 Move towards harmonisation 
It is submitted that there should be no rush to legislate or introduce new polices for biobank 
research in Africa. First there must be an understanding of the governance framework in place and a 
consideration of the features of good governance for biobank research. However, there have been 
calls for harmonisation and it has been demonstrated that differing policies can impede 
collaborations in Europe. Despite the adaptability and flexibility of a PBR framework, there is the 
need for some form of legislation and enforcement powers. The abuses exposed in the Havasupai 
tribe case whereby samples were collected for a study on diabetes but used in studies on 
schizophrenia, inbreeding and evolutionary genetics that challenged the Tribes own account of its 
origins, demonstrate that researchers will not always have the best interests of the donors at 
heart.101  
However, how can these differing national frameworks be accommodated considering the 
internationalisation of the research? Despite calls for harmonisation, the cultural diversity in Africa 
as well as the differing governance approaches, leads one to conclude that harmonisation is unlikely 
to be successful. Attempts at harmonising strict with liberal policies often results in the creation of a 
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framework that is comprised of the rules of the strictest regime.102 In Europe, projects that sought to 
“aim for the highest legal standard in a project” with the aim of meeting the legal requirements in 
each jurisdiction, found that they had to leave collaborators with onerous national requirements out 
of the project as they could not meet these strict national requirements.103 
How can Africa deal with these conflicting regulations so as not to impede upon collaborations? The 
“minimal threshold of policy harmonization” is favoured by some cross country biobank projects.104  
Another solution is the coordinating principle whereby tissue samples are handled in accordance 
with the rules of the country that they were obtained from.105 This rule was adopted by Tubafrost 
who opted not to introduce their own polices in light of the differing policies and regulations across 
Europe as they believed that national policies diverged to such an extent that consensus would have 
been impossible.106 There was the concern that if an attempt at consensus was made, it would have 
resulted in the strictest regime being implemented, to the detriment of those countries where a 
more liberal regime was in place.107 Thus Tubafrost opted for a coordinating principle based on the 
home country rule whereby the rules of the home country dictates whether the sample can be used 
abroad:  
“if tissue may legitimately used for a certain kind of research in the country where it was 
taken and under whose jurisdiction the patient falls, it may also be used for such research in 
the country where it is sent to in the context of a scientific program even if in that other 
country other regulations would apply for research with residual tissue taken from patients 
under their jurisdiction’.108  
Until such time as a pan-African response to biobank research is possible, or the coordinating 
principle is adopted, H3Africa should be cognisant of the experiences of Europe and perhaps follow 
the example of Tubafrost in declining to introduce new policies that confuse matters. Rather its 
energy should be spent on the development of a WIKIE+ legal platform similar to that of BBMRI-ERIC 
that describes the legal situation in each country. Such a development could help African 
researchers navigate the governance framework that exists in each country. 
3.3 Biological data 
The unique features of biobank research causes us to reassess previously held ideals about the 
ethical conduct of research. However the greatest risk in this research is confidentiality. As DNA is an 
identifier, confidentiality can no longer be guaranteed.109 Furthermore, considerable data comes 
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from these samples and it is unclear how this data should be treated and protected. Biobank 
governance in Africa is generally accommodated within the existing protection of human 
participants in research that often does not have much consideration of biological data. In 
September 2015, the South African insurance company Discovery announced that on foot of a deal 
with a US company, they would offer genetic testing for $250. Of concern is that their de-identified 
data would be stored in the US.110 South Africa has currently no legislation in place to deal with 
these issues and it is not alone as it has not been subject to the same oversight as biological samples. 
However the value and need to protect this data must not be underestimated as it is the linkage of 
data with samples that gives the sample scientific value.111 In Europe, the biological sample and data 
from the sample are treated as being legally distinct. This distinction is challenged on the grounds 
that genetic material “is both information and bodily sample” creating uncertainty at times as to 
what should be considered data or a sample.112 
Material transfer agreements (MTAs) and data sharing agreements can make up for policy gaps and 
establish agreements on which data is shared. However the original consent may not contain any 
reference to data. Should restrictions on the use and transfer of samples apply to data? Since this is 
an area that many African jurisdictions have not considered,113 the control on the use of biological 
data is one area in which there could be a pan African response. The European experience has 
demonstrated that full harmonisation in this area is unlikely, but the conversation must be started 
on the protection of data and whether it should be on par with that of samples. Treating samples 
and data as being legally distinct may be a difficult concept for many researchers to grasp 
considering their interconnectedness, but an African response is necessary. As one of the greatest 
risks in biobank research, confidentiality of participants must be protected and this must extend to 
their biological data.  
4. Conclusions 
Genomic biobank research in Africa is entering an exciting and promising phase. Biobanks are 
increasingly interconnected networks and harmonisation of governance across the continent can 
assist in the development of collaborations. However biobanks have been developed over time and 
there has been an ad hoc and often local response to their governance. These frameworks must now 
oversee research that is increasingly conducted at an international level. UNESCO’s International 
Declaration on Human Genetic Data calls for states to regulate the international transfer of data and 
samples to foster international collaborations. This is certainly an aspiration of many, but has not 
been possible within Europe due to the multitude of bodies that have the power to develop 
guidelines, policies, legalisation and directives making it difficult to agree on one set of rules or 
principles. 
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In response to new technologies, there is often the perceived need that the government ought to do 
something, often in the form of regulation.114 However there should be some coordinated 
international response and as a consortium with expertise in science, law and ethics, H3Africa is 
ideally situated to start this conversation. H3Africa can lead this discussion. It should not use its 
pivotal position to develop new and possibly unnecessary guidelines, but rather lead a discussion on 
the principles of good governance and the role it can play in achieving harmonisation. The 
conversation should begin by focusing on the importance of establishing good governance principles 
that should underpin a biobank framework. The system should be transparent, proportionate, and 
consistent, while allowing for flexibility and legitimate and it should create an environment that 
fosters collaboration, while ensuring public trust. Thus, moving forward, Africa must start a 
discussion on the governance of biobanks and how it can be structured in such a way that promotes 
collaborative research across the continent. 
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